Navigation Links
WestPark Capital Announces $2.6 Million IsoRay Offering
Date:12/2/2011

LOS ANGELES, December 2, 2011 /PRNewswire/ -- WestPark Capital, Inc. announced the completion of a public offering for IsoRay, Inc. (NYSE Amex: ISR). A total of 2,817,988 shares of common stock and warrants to purchase up to 563,598 shares of common stock were sold, generating gross proceeds of $2,592,549 in the offering. Proceeds from the offering will be used to fund new applications for IsoRay's Cesium-131 technology to treat lung, head and neck, breast and brain cancers, and for working capital and general corporate purposes. WestPark Capital, Inc. acted as lead manager for the offering. This offering was originated through Tekesta Capital Partners, a division of WestPark Capital, Inc.

This press release does not constitute an offer to sell or the solicitation of offers to buy any security and shall not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The offering was made only by prospectus. A prospectus supplement relating to the common stock and warrants issued in the offering has been declared effective by the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained at the SEC website at www.sec.gov, or via written request to WestPark Capital, Inc., 1900 Avenue of the Stars, Suite 310, Los Angeles, California 90067.

About WestPark Capital, Inc.

WestPark Capital is a leading investment banking and securities brokerage firm serving the needs of private and public growth companies worldwide. WestPark is committed to forging lasting partnerships with emerging growth companies and the investors who back them.  WestPark provides a comprehensive range of corporate finance services, including initial public offerings, reverse mergers, follow-on offerings, private placements and corporate finance advisory services. Additional information about WestPark Capital, Inc. is available at www.wpcapital.com or at info@wpcapital.com.

About IsoRay, Inc.

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the exclusive producer of Cesium-131 internal radiation therapy, which is expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com.

Contact:

WestPark Capital, Inc.
Richard Rappaport, CEO
310) 843-9300


'/>"/>
SOURCE WestPark Capital, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Physicians Capital Investments Announces Pedro Vergne-Marini, MD Named to Beckers ASC Review "350 People in the ASC Industry to Know"
2. Radient Pharmaceuticals Corporation Receives $500,000 in New Capital
3. IsZo Capital Writes to Special Committee of Taro Pharmaceutical Opposing Sun Pharmaceutical Offer and Liability Protection Management Proposals
4. Radient Pharmaceuticals Corporation Completes Restructurings with Institutional Investors to Limit Conversions and Stock Sales and Provide for Potential Additional Capital
5. Alacrita Launches Charity Auction of Executive One-to One Lunches with Senior Figures from the Pharmaceutical and Venture Capital Industries
6. Machine Solutions Inc. Partners With Forsyth Capital Investors, LLC
7. Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference
8. Quest Diagnostics to Speak at the Lazard Capital Markets 8th Annual Healthcare Conference
9. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference
10. Accuray Incorporateds CEO to Speak at Lazard Capital Markets 8th Annual Healthcare Conference and Stephens Fall Investment Conference
11. HeartWare to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- New England Pediatric Device Consortium (NEPDC) announced Velano ... and in-kind service towards the commercialization of the company,s ... blood draws less traumatic for children could go a ... We,re looking forward to working with Velano Vascular to ... the kids we treat," said Ann-Christine Duhaime , ...
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research and ... Size, Share, Development, Growth and Demand Forecast to 2022" report to ... The global ... expected to grow at a CAGR of 6.7% during 2016-2022 ... segment held the largest share in the global market in 2015. Among ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... report to their offering. ... This report analyzes the worldwide markets for Dental Implants in US$ ... Canada , Japan , Europe ... and Rest of World. Annual estimates and forecasts are ...
Breaking Medicine Technology:
(Date:3/27/2017)... MA (PRWEB) , ... March 27, 2017 , ... ... Group, the organization behind the New England Journal of Medicine and NEJM Journal ... NEJM Knowledge+ Pediatrics Board Review was created by a panel of pediatricians from ...
(Date:3/27/2017)... ... 27, 2017 , ... American Veterinarian™, the leading multimedia provider ... announces the launch of Veterinarian’s Money Digest™, a business and financial resource for ... American Veterinarian™. , “We look forward to launching Veterinarian’s Money Digest™,” ...
(Date:3/27/2017)... ... 27, 2017 , ... Advantexe Learning Solutions , a ... a new research study, The Business Readiness Report. The report explores the correlation ... the actual success of achieving individual and company goals. , There are ...
(Date:3/27/2017)... ... 2017 , ... The Association of Healthcare and Value Analysis ... first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will provide the Keynote ... analysis professionals have a ‘seat at the table’ with clinical committees when it ...
(Date:3/27/2017)... ... , ... The Anaheim Hills office accelerates and supports FNCC’s growth and further ... sales professionals over the past 6 months and is continuing to recruit new talent ... course of 2017. , “This new office is a direct result of our ...
Breaking Medicine News(10 mins):